Skip survey header

BLADDR 2020 case 2 - Grivas

Thank You!

Your case challenge

View case
 
What would Petros Grivas do?

Until a few months ago, the answer was observation, regular follow-up. But now, after the presentation by Dr. Tom Powles at the ASCO virtual meeting, the answer has changed. We have to start switch-maintenance with avelumab based on the phase III randomised JAVELIN bladder 100 trial.
 

References
Powles T, et al. Maintenance avelumab + best supportive care versus best supportive care alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma: JAVELIN Bladder 100 phase III interim analysis. J Clin Oncol 2020;38(Suppl 18):abs.LBA1

Conflict of interest form Petros Grivas

 
What would Petros Grivas do?

Until a few months ago, the answer was observation, regular follow-up. But now, after the presentation by Dr. Tom Powles at the ASCO virtual meeting, the answer has changed. We have to start switch-maintenance with avelumab based on the phase III randomised JAVELIN bladder 100 trial.




References
Powles T, et al. Maintenance avelumab + best supportive care versus best supportive care alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma: JAVELIN Bladder 100 phase III interim analysis. J Clin Oncol 2020;38(Suppl 18):abs.LBA1
References
Powles T, et al. Maintenance avelumab + best supportive care versus best supportive care alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma: JAVELIN Bladder 100 phase III interim analysis. J Clin Oncol 2020;38(Suppl 18):abs.LBA1

Conflict of interest form Petros Grivas


 
I hope you can join us during the live panel discussion of virtual BLADDR 2020 on 15 October to further discuss these data.

Reserve your seat